NeuroPace, Inc. (NASDAQ:NPCE) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• NeuroPace, Inc. has received a consensus rating of "Moderate Buy" from analysts, with one hold recommendation and five buy recommendations.
• The company reported a quarterly earnings loss of ($0.26) per share, missing the consensus estimate of ($0.24), despite revenue exceeding estimates at $23.52 million.
• Large institutional investors have increased their stakes in NeuroPace, with a significant 83.6% increase in holdings from Ameritas Investment Partners in the second quarter.

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $16.60.

A number of analysts have issued reports on the company. Zacks Research lowered NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. HC Wainwright assumed coverage on NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price target on the stock. Finally, Wells Fargo & Company decreased their price target on NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th.

NeuroPace Stock Down 1.5%

NPCE opened at $9.86 on Friday. The company has a quick ratio of 4.51, a current ratio of 5.47 and a debt-to-equity ratio of 3.02. The firm has a market cap of $326.17 million, a P/E ratio of -11.74 and a beta of 1.90. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.98. The business's fifty day simple moving average is $9.20 and its 200 day simple moving average is $11.16.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%.The business had revenue of $23.52 million during the quarter, compared to analyst estimates of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that NeuroPace will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On NeuroPace

Large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its holdings in shares of NeuroPace by 83.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock worth $27,000 after purchasing an additional 1,118 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of NeuroPace in the 4th quarter worth about $29,000. Legal & General Group Plc raised its holdings in shares of NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after purchasing an additional 1,239 shares during the period. Quantbot Technologies LP purchased a new position in shares of NeuroPace in the 2nd quarter worth about $35,000. Finally, GAMMA Investing LLC purchased a new position in shares of NeuroPace in the 1st quarter worth about $53,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.